In this episode of The Oncology Insights Podcast, I speak with Dr. Xiuning Le, Associate Professor and Section Chief at The University of Texas MD Anderson Cancer Center, about the evolution of precision medicine in lung cancer. We discuss actionable mutations, targeted therapies, immunotherapy, early detection strategies, brain metastases, and emerging innovations shaping the future of oncology care. Listen now on all major platforms!

"Targeted therapies are developed by understanding which oncogenic pathways drive tumor growth and identifying methods to overcome treatment resistance."

Meet the guest: Dr. Xiuning Le is a tenured Associate Professor and Section Chief in Thoracic and Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. Her research focuses on oncogene driven non small cell lung cancer, targeted therapies, brain metastases, and translational oncology. She has led clinical trials that contributed to new standards of care and FDA approvals. Listen to Dr. Xiuning Le on The Oncology Insights Podcast, available on all major platforms.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (00:52) Introduction
• (05:38) Precision oncology
• (12:27) Actionable mutations
• (19:38) Immunotherapy biomarkers
• (25:14) Early detection
• (29:11) Brain metastases
• (32:20) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

YouTube: The Oncology Insights Podcast

Facebook: The Oncology Insights Podcast

TikTok: The Oncology Insights Podcast